VIDEO: Triple all-oral combination could be option for myeloid leukemia
In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the SAVE trial into the use of menin inhibitors in patients with leukemia.
DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted the study, which looked into a triple all-oral combination of revumenib (Revuforj, Syndax Pharmaceuticals), decitabine/cedazuridine (Inqovi; Astex Pharmaceuticals, Taiho Oncology) and venetoclax (Venclexta; AbbVie, Genentech) in myeloid leukemia.
“Thinking forward, this is likely to represent at least one option for patients with myeloid leukemia in the relapse/refractory center — or maybe even up front. So, it was encouraging to see this data presented,” DeAngelo said.
Reference:
- Issa GC, et al. Abstract 216. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Collapse
Healio Interviews
Read more about